Rani Therapeutics Holdings (RANI) Asset Utilization Ratio (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted Asset Utilization Ratio of 0.09 for Q2 2026, up 50.86% on a QoQ basis from 0.06 in Q1 2026, and up 47.91% year-over-year from 0.06 in Q2 2025.
Analysis
Rani Therapeutics Holdings (RANI) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Asset Utilization Ratio for 5 years, with the latest figure at 0.09 in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio rose 47.91% year-over-year to 0.09 in Q2 2026; TTM through Jun 2026 was 0.09, a 47.91% increase from a year earlier, with the FY2025 full-year figure at 0.03, up 57.68% from the prior year.
- Asset Utilization Ratio was 0.09 for Q2 2026 at Rani Therapeutics Holdings, up from 0.06 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.09 in Q3 2025, with the low at 0.02 in Q2 2022.
- Average Asset Utilization Ratio over 4 years is 0.05, with a median of 0.05 recorded in 2025.
- The sharpest annual moves came in 2025 and 2026: Asset Utilization Ratio soared 85.22% in 2025, then soared 45.21% in 2026.
- Over 4 years, Asset Utilization Ratio stood at 0.02 in 2022, then soared by 43.62% to 0.03 in 2024, then jumped by 85.22% to 0.05 in 2025, then jumped by 82.18% to 0.09 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.09 (Q2 2026), 0.06 (Q1 2026), and 0.05 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 0.00 |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | 0.09 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.09 |
| Mar 31, 2026 | 0.06 |
| Dec 31, 2025 | 0.05 |
| Sep 30, 2025 | 0.09 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.03 |
| Jun 30, 2022 | 0.02 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.03 |